Mar 15 |
Iterum Therapeutics to Participate in H.C. Wainwright Virtual @Home Fireside Chat
|
Mar 7 |
Iterum (ITRM) Plans Early Submission of UTI Drug NDA, Stock Up
|
Mar 6 |
Iterum spikes on accelerated timeline for FDA filing
|
Mar 6 |
Iterum Therapeutics Provides Business Update
|
Feb 1 |
Steven Cohen's Point72 Asset Management Acquires New Stake in Iterum Therapeutics PLC
|
Jan 30 |
Iterum meets main goal in late trial for uUTI treatment with oral sulopenem
|
Jan 30 |
Iterum Therapeutics Announces Positive Topline Results from its Phase 3 REASSURE Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections
|
Dec 28 |
Insiders Buying Iterum Therapeutics And 3 Other Stocks Under $3
|
Dec 4 |
Iterum Therapeutics regains compliance with Nasdaq's minimum bid price rule
|
Dec 4 |
Iterum Therapeutics Regains Compliance with Nasdaq Bid Price Rule
|